Genesee Capital Advisors LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Genesee Capital Advisors LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,612 shares of the biopharmaceutical company’s stock, valued at approximately $249,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Olistico Wealth LLC purchased a new stake in shares of Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer during the second quarter worth about $29,000. Quarry LP purchased a new stake in shares of Pfizer during the second quarter worth about $31,000. Trivant Custom Portfolio Group LLC grew its holdings in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. purchased a new stake in shares of Pfizer during the second quarter worth about $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Thursday, October 3rd. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday. They issued a “market perform” rating and a $32.00 target price for the company. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Finally, Wells Fargo & Company boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $33.91.

Pfizer Stock Down 1.0 %

PFE traded down $0.29 during trading on Monday, hitting $28.93. The company had a trading volume of 13,213,070 shares, compared to its average volume of 36,989,422. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The business has a 50-day moving average of $29.07 and a 200-day moving average of $28.45. The company has a market cap of $163.93 billion, a PE ratio of -483.67, a P/E/G ratio of 1.02 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.81%. Pfizer’s dividend payout ratio is currently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.